TVTX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Travere Therapeutics receives USPTO Notice of Allowance for a patent application covering certain methods of using FILSPARI in focal segmental glomerulosclerosisSep 23, 2026
- Travere Therapeutics receives U.S. patent allowance related to FILSPARI use in IgA nephropathyMay 28, 2026
- Travere secured full FDA approval for FILSPARI, the first approved treatment for FSGSApr 14, 2026
- Travere Therapeutics provides update on FDA advisory committee meeting for FILSPARI® (sparsentan) in FSGSSep 10, 2025
- Travere Therapeutics announces FDA approval of REMS modification for FILSPARI® (sparsentan) in IgA nephropathyAug 29, 2025